Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SHE:300534)
China flag China · Delayed Price · Currency is CNY
12.54
-0.70 (-5.29%)
Sep 10, 2026, 2:40 PM CST

SHE:300534 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
726.21865.261,0281,067788.26280.05
Other Revenue
11.6921.714.8812.8911.427.77
737.9886.961,0431,080799.68287.81
Revenue Growth
-24.96%-14.92%-3.48%35.06%177.85%12.91%
Cost of Revenue
248.29283.41291.37386.79341.62195.48
Gross Profit
489.61603.55751.13693.26458.0692.33
Selling, General & Admin
381.36467.9617.94560.01364.3790.06
Research & Development
24.2827.1528.1330.1727.126.7
Other Operating Expenses
6.0613.5613.2212.344.993.75
Operating Expenses
417.41516.08655.12611.43401.75101.65
Operating Income
72.287.4796.0281.8256.31-9.31
Interest Expense
-1.37-2.66-3.34-3.95-0.5-0.53
Interest & Investment Income
2.864.747.397.174.32.32
Currency Exchange Gain (Loss)
-0.01-0.01-00.010.02-0.06
Other Non Operating Income (Expenses)
8.880.11-2.0602.1-0.11
EBT Excluding Unusual Items
82.5689.669885.0562.24-7.7
Impairment of Goodwill
------4.78
Gain (Loss) on Sale of Investments
-0-0-0.21---
Gain (Loss) on Sale of Assets
-0.06-0.01-0.69-0.24-0.06
Asset Writedown
-0.42----0.1-
Other Unusual Items
-4.5-8.54.6612.247.67
Pretax Income
77.5781.15101.7697.0266.14-4.75
Income Tax Expense
22.0615.7851.6813.1717.491.55
Earnings From Continuing Operations
55.5165.3650.0883.8548.65-6.3
Minority Interest in Earnings
-20.83-21.41-25.6-22.2-9.87-2.81
Net Income
34.6743.9524.4861.6538.79-9.11
Net Income to Common
34.6743.9524.4861.6538.79-9.11
Net Income Growth
35.79%79.56%-60.30%58.95%--
Shares Outstanding (Basic)
303303303303303304
Shares Outstanding (Diluted)
303303303303303304
Shares Change
0.02%0.01%-0.03%0.05%-0.10%-0.54%
EPS (Basic)
0.110.140.080.200.13-0.03
EPS (Diluted)
0.110.140.080.200.13-0.03
EPS Growth
35.77%79.55%-60.28%58.87%--

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
11.49-49.9137.23-29.83242.0350.72
Free Cash Flow Per Share
0.04-0.170.45-0.100.800.17
Dividend Per Share
0.0200.0400.0400.020--
Dividend Growth
-50.00%0%100.00%---
Gross Margin
66.35%68.05%72.05%64.19%57.28%32.08%
Operating Margin
9.79%9.86%9.21%7.58%7.04%-3.24%
Profit Margin
4.70%4.96%2.35%5.71%4.85%-3.16%
Free Cash Flow Margin
1.56%-5.63%13.16%-2.76%30.27%17.62%
EBITDA
116.76129.18134.51111.7383.313.25
EBITDA Margin
15.82%14.56%12.90%10.34%10.42%4.60%
D&A For EBITDA
44.5641.7138.529.926.9922.56
EBIT
72.287.4796.0281.8256.31-9.31
EBIT Margin
9.79%9.86%9.21%7.58%7.04%-3.24%
Effective Tax Rate
28.44%19.45%50.78%13.57%26.44%-
Revenue as Reported
612.28886.961,0431,080799.68287.81
Advertising Expenses
-0.690.95---